PMID- 27470062
OWN - NLM
STAT- MEDLINE
DCOM- 20170508
LR  - 20170508
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 170
DP  - 2016 Oct
TI  - Anti-TNFalpha Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
PG  - 32-40
LID - S0002-9394(16)30360-9 [pii]
LID - 10.1016/j.ajo.2016.07.016 [doi]
AB  - PURPOSE: To assess the long-term efficacy of the most widely used anti-tumor 
      necrosis factor alpha (TNFalpha) agents for treatment of HLA-B27-positive ankylosing 
      spondylitis (AS)-related uveitis. DESIGN: Retrospective cohort study. METHODS: 
      The medical records of 143 patients with HLA-B27-positive AS who visited Seoul 
      St. Mary's Hospital and were taking an anti-TNFalpha agent for at least 1 year were 
      studied. Subjects were divided into 3 groups according to anti-TNFalpha treatment: 
      Group 1 (infliximab, 66), Group 2 (adalimumab, 45), and Group 3 (etanercept, 32). 
      RESULTS: Mean age was 41.0 +/- 13.0 years, and 97 patients (67.8%) were male. Mean 
      follow-up period was 70.6 +/- 37.9 months. In cases of active ocular inflammation 
      at the onset of anti-TNFalpha treatment, patients showed improved activity of uveitis 
      after 24.0 +/- 15.0 days (Group 1), 17.9 +/- 6.0 days (Group 2), and 25.9 +/- 18.0 days 
      (Group 3). After the anti-TNFalpha treatment, 71 of 94 patients (32 [76.2%] in Group 
      1, 26 [78.8%] in Group 2, and 13 [68.4%] in Group 3) remained without uveitis 
      relapse. A reduction in the number of systemic medications was achieved in 129 
      patients (90.2%). Twenty-eight cases of minor side effects were observed, and 4 
      cases were tuberculosis leading to discontinuation of anti-TNFalpha treatment. 
      CONCLUSIONS: Infliximab, adalimumab, and etanercept were effective for treating 
      and reducing the number of uveitis relapses in HLA-B27-positive AS. However, the 
      risk of serious infections was noted, so ophthalmologists should consider the 
      possibility that prolonged use of biologic agents may result in systemic side 
      effects.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kim, Mirinae
AU  - Kim M
AD  - Department of Ophthalmology and Visual Science, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
FAU - Won, Jae-Yon
AU  - Won JY
AD  - Department of Ophthalmology and Visual Science, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
FAU - Choi, Seung Yong
AU  - Choi SY
AD  - Department of Ophthalmology and Visual Science, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
FAU - Ju, Ji Hyeon
AU  - Ju JH
AD  - Department of Rheumatology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
FAU - Park, Young-Hoon
AU  - Park YH
AD  - Department of Ophthalmology and Visual Science, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea. Electronic address: 
      parkyh@catholic.ac.kr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20160725
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Antirheumatic Agents)
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Cohort Studies
MH  - Etanercept/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - HLA-B27 Antigen/*immunology
MH  - Humans
MH  - Infliximab/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Spondylitis, Ankylosing/*drug therapy/immunology/physiopathology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Uveitis/*drug therapy/immunology/physiopathology
EDAT- 2016/07/30 06:00
MHDA- 2017/05/10 06:00
CRDT- 2016/07/30 06:00
PHST- 2016/04/29 00:00 [received]
PHST- 2016/07/09 00:00 [revised]
PHST- 2016/07/18 00:00 [accepted]
PHST- 2016/07/30 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
PHST- 2016/07/30 06:00 [entrez]
AID - S0002-9394(16)30360-9 [pii]
AID - 10.1016/j.ajo.2016.07.016 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2016 Oct;170:32-40. doi: 10.1016/j.ajo.2016.07.016. Epub 2016 
      Jul 25.